| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3055739 | Experimental Neurology | 2011 | 5 Pages |
Abstract
The use of immunotherapy for Alzheimer's disease (AD) has traditionally focused on the amyloid-β (Aβ) peptide and has shown great potential in both animal and human studies. However, an emerging body of work has begun to concentrate on tau and to develop immunization protocols designed to decrease tau pathology in AD and other tauopathies. This commentary will discuss the use of immunotherapy for AD, focusing on tau immunotherapy in the context of recent reports on the use of tau phospho-peptides in transgenic models of tau pathology.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Kiren Ubhi, Eliezer Masliah,